Search

Your search keyword '"Chopra V"' showing total 1,294 results

Search Constraints

Start Over You searched for: Author "Chopra V" Remove constraint Author: "Chopra V"
1,294 results on '"Chopra V"'

Search Results

1. Impact of COVID-19 on heart failure hospitalization and outcome in India – A cardiological society of India study (CSI–HF in COVID 19 times study – 'The COVID C–HF study')

2. Comparison of Iridocorneal Angle Assessments in Open-Angle Glaucoma and Ocular Hypertension Patients: Anterior Segment Optical Coherence Tomography and Gonioscopy

3. Southern Saskatchewan Ticagrelor Registry experience

5. Heart Failure in Different Asian Populations

6. Effect of Packing Factor on the Electrical Performance of Semitransparent Photovoltaic Thermal (SPVT) System: An Experimental Approach

7. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

8. Association Between Number of Lumens and Peripherally Inserted Central Catheter Complications in Patients Admitted to the Intensive Care Unit

11. Contributors

17. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

19. Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations.

22. Empagliflozin in heart failure with a preserved ejection fraction

23. Advancing rheumatic disease treatment: A journey towards better lives

24. Cardiovascular and renal outcomes with empagliflozin in heart failure

25. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

27. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

31. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

36. Genome Manipulations

38. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

39. Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

40. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

41. Cardiovascular and renal outcomes with empagliflozin in heart failure

44. Audit Commission Tackles Anaesthetic Services

46. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Catalog

Books, media, physical & digital resources